Stem cell innovation in the USA: The benefits of the minimal state

Regenerative Medicine

Volumn 3, Issue 4, 2008, Pages 597-610

  Salter, Brian G ^a   Harvey, Olivia ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Innovation; Market; Patenting; Regulation; States; Stem cells; USA

Indexed keywords

ARTICLE; BIOTECHNOLOGICAL PRODUCTION; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; EMBRYO RESEARCH; EMBRYONIC STEM CELL; FORECASTING; FUNDING; GOVERNMENT REGULATION; HUMAN; INTERNATIONAL RELATIONS; MEDICAL RESEARCH; MEDICAL SOCIETY; NONHUMAN; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; RESEARCH SUBJECT; STEM CELL TRANSPLANTATION; UNITED STATES; ECONOMIC ASPECT; ECONOMICS; POLICY; REVIEW; STEM CELL;

BIOMEDICAL RESEARCH; ECONOMIC COMPETITION; GOVERNMENT REGULATION; HUMANS; PUBLIC POLICY; STEM CELLS; UNITED STATES;

EID: 49149119070     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460751.3.4.597     Document Type: Article

References (42)

1. UK Stem Cell Initiative: Report and Recommendations, Department of Health (2006).
2. UK Stem Cell Initiative: Report and Recommendations, Department of Health 5 (2006).
3. Pincock S: Britain's brain gain. Lancet 364(9429), 127-128 (2004).
4. Salter B, Cooper M, Dickins A: China and the global stem cell bioeconomy: an emerging political strategy? Regen. Med. 1(5), 671-683 (2006).
5. Noll R: Designing an effective programme of state-sponsored human embryonic stem cell research. Berkeley Technol. Law J. 21(3), 1143-1174 (2006).
6. British Standards Institution: Guidance on codes of practice, standardised methods and regulations for cell-based therapeutics from basic research to clinical application. PAS 83. London. British Standards Institute (2006).
7. Biophoenix: Opportunities in stem cell research and commercialisation. Business Insights. London (2006).
8. Cookson C: Country Report: China. Financ. Times 17 June (2005).
9. Gottweis H, Triendl R: South Korean policy failure and the Hwang debacle. Nat. Biotech. 24, 141-143 (2006).
10. Kim TG: $450 million budget set for stem cell research. The Korean Times, 29 May, (2006).
11. Webb S: A patchwork quilt of funding. Nat. Rep. Stem Cells 1 November (2007).
12. Shorrett P, Rabinow P, Billings PR: the changing norms of the life sciences. Nat. Biotech. 21, 123-125 (2003).
13. Wilan KH: Chasing biotech, state by state: winners and losers. Nat. Biotech. 23(2), 175-179 (2005).
14. Cooke P: New economy innovation systems: biotechnology in Europe and the USA. Ind. Innov. 8(3), 267-289 (2001).
15. Cortright J, Mayer H: Signs of life: the growth of biotechnology centres in the US. Washington DC: Brookings Institution Centre on Urban and Metropolitan Policy (2002).
16. Levine A: Research policy and the mobility of US stem cell scientists. Nat. Biotech. 24, 865-866 (2006).
17. National Science Board: Science and Engineering Indicators. Arlington, VA, UAS: National Science Foundation. Tables 3-50 (2008).
18. National Science Board: Science and Engineering Indicators. Arlington, VA, USA: National Science Foundation. Tables 3-26 (2008).
19. National Science Board: Science and Engineering Indicators. Arlington, VA, USA: National Science Foundation. Tables 3-34 (2008).
20. Salter B, Cooper M, Dickins A: China and the global stem cell bioeconomy: an emerging political strategy. Regen. Med. 1(5), 675 (2006).
21. Salter B, Cooper M, Dickins A, Cardo V: Stem cell science in India: emerging economies and the politics of globalisation Regen. Med. 2(1), 78 (2007).
22. National Science Board: Science and Engineering Indicators. Arlington VA, USA: National Science Foundation. 3-48/49 (2008).
23. Zweig D: Competing for talent: China's strategies to reverse the brain drain. Int. Labour Rev. 145(1/2), 65-89 (2006).
24. Hunter J: Before the shooting begins: searching for democracy in America's culture war. The Free Press New York, USA (1994).
25. President's Council on Bioethics: Human cloning and human dignity: an ethical inquiry. Washington: President's Council on Bioethics (2002).
26. President's Council on Bioethics: Monitoring stem cell research, Washington: President's Council on Bioethics (2004).
27. President's Council on Bioethics: Alternative sources of human pluripotent stem cells, White Paper, Washington: President's Council on Bioethics (2005).
28. National Academy of Sciences: Guidelines for human embryonic stem cell research, Washington: National Academies Press.
29. Halme D, Kessler D: FDA regulation of stem cell-based therapies. N. Engl. J. Med. 355(160), 1730-1735 (2006).
30. Food and Drug Administration, Department of Health and Human Services: Human cells, tissues and cellular and tissue based products, Code of Federal Regulations. Title 21. Part 127.1 (2006).
31. Martin P, Coveney C, Kraft A et al.: Commercial development of stem cell technology: lessons from the past, strategies for the future. Regen. Med. 1(6), 801-807 (2006).
32. Salter B: Patenting, morality and human embryonic stem cell science: bioethics and cultural politics in Europe. Regen. Med. 2(3), 301-311 (2007).
33. Bonetta L: European stem cell patents: taking the moral high road. Cell 132, 514-516 (2008).
34. Mowery D, Sampat B: The Bayh-Dole Act of 1980 and university-industry technology transfer: a model for other OECD governments? J. Tech. Trans. 30(1-2), 115-127 (2004).
35. Rai A, Eisenberg R: Bayh-Dole reform and the progress of biomedicine. Law Contem. Probs. 66, 289-314 (2003).
36. Rabin S: The gatekeepers of hES cell products. Nat. Biotech. 23, 817-819 (2005).
37. Murray F, Stern S: Do formal intellectual property rights hinder the free flow of scientific knowledge? An empirical test of the anti-commons hypothesis. J. Econ. Behav. Organ. 63(4), 648-687 (2007).
38. Stem Cell Business News Top stem cell scientists argue against Thomson/ WARF patents. Stem Cell Bus. News 5 July (2007).
39. Taymor K, Scott C, Greely H: The paths around stem cell intellectual property. Nat. Biotech, 24(4), 411-413 (2006).
40. Plomer A, Taymor K, Scott C: Challenges to human embryonic stem cell patents. Cell Stem Cell 2, 13-17 (2008).
41. Marks and Clerk Patent and Trademark Attorneys: The Marks and Clerk Biotechnology Report 2005, London, UK: Marks and Clerk Patent and Trademark Attorneys(2005).
42. Regalado A: Big companies quietly pursue research on embryonic stem cells. The Wall Street Journal 12 April (2005).